TXG
10x Genomics, Inc. · Healthcare · Medical - Healthcare Information Services
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 114 | +7 | 98.90M | $3.78B | +16 | −8 |
| Q1 2026 | 109 | +3 | 94.02M | $1.99B | +12 | −10 |
| Q4 2025 | 107 | +3 | 97.86M | $1.59B | +4 | — |
| Q3 2025 | 19 | -2 | 71.88M | $839.83M | — | −3 |
| Q2 2025 | 19 | +1 | 64.66M | $748.72M | +2 | −1 |
| Q1 2025 | 15 | 0 | 30.56M | $266.82M | +1 | −1 |
| Q4 2024 | 15 | +1 | 24.83M | $356.61M | +3 | −2 |
| Q3 2024 | 13 | 0 | 22.71M | $512.82M | +1 | −1 |
| Q2 2024 | 13 | — | 21.07M | $409.76M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 9.31M | — | $181.15M | 1.6% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 2.87M | — | $55.90M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 2.87M | — | $55.90M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 2.74M | — | $53.33M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Baillie Gifford ✦ | 2.74M | — | $53.33M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Baillie Gifford ✦ | 2.74M | — | $53.33M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Baillie Gifford ✦ | 2.74M | — | $53.33M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (pasivo) | 1.77M | — | $34.49M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (pasivo) | 1.77M | — | $34.49M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 1.36M | — | $26.47M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Norges Bank ✦ (pasivo) | 991.05K | — | $19.28M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Capital World Investors ✦ | 793.30K | — | $15.43M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 334.39K | — | $6.50M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 315.18K | — | $6.13M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 315.18K | — | $6.13M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 315.18K | — | $6.13M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 210.20K | — | $4.09M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | PRIMECAP Management ✦ | 186.80K | — | $3.63M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 136.78K | — | $2.66M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Marshall Wace ✦ | 35.40K | — | $688,550 | 0.0% | n/c | 1 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 328 tenedores, 124.40M acciones, $2.59B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Director · 2.27K acc. · $129,902
Director · 5.28K acc. · $302,377
Director · 17.00K acc. · $978,880
Director · 3.00K acc. · $176,175
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología